Bio-Rad Laboratories, Inc. (NYSE:BIO - Get Free Report) shares traded down 5% during mid-day trading on Friday . The company traded as low as $235.81 and last traded at $237.18. 50,982 shares were traded during mid-day trading, a decline of 84% from the average session volume of 312,569 shares. The stock had previously closed at $249.74.
Wall Street Analyst Weigh In
Several analysts have weighed in on the stock. StockNews.com lowered shares of Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Wells Fargo & Company lowered their target price on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 17th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $380.20.
Get Our Latest Stock Analysis on BIO
Bio-Rad Laboratories Price Performance
The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $6.70 billion, a P/E ratio of -3.68 and a beta of 1.12. The company's fifty day moving average price is $251.85 and its 200 day moving average price is $309.16.
Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, sell-side analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.
Institutional Investors Weigh In On Bio-Rad Laboratories
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Venturi Wealth Management LLC lifted its stake in shares of Bio-Rad Laboratories by 2,175.0% during the 4th quarter. Venturi Wealth Management LLC now owns 91 shares of the medical research company's stock valued at $30,000 after buying an additional 87 shares in the last quarter. GeoWealth Management LLC raised its stake in shares of Bio-Rad Laboratories by 342.9% during the 4th quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after purchasing an additional 72 shares during the period. Picton Mahoney Asset Management lifted its holdings in Bio-Rad Laboratories by 55.6% during the 4th quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock worth $32,000 after purchasing an additional 35 shares in the last quarter. Asset Planning Inc bought a new position in Bio-Rad Laboratories in the 4th quarter worth about $33,000. Finally, Curat Global LLC purchased a new position in Bio-Rad Laboratories during the 1st quarter valued at about $34,000. 65.24% of the stock is owned by institutional investors.
Bio-Rad Laboratories Company Profile
(
Get Free Report)
Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Rad Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Rad Laboratories wasn't on the list.
While Bio-Rad Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
